England’s National Health Service (NHS) says that it has saved £110 million (US $134 million) by implementing its policy to use the best-value adalimumab after the brand-name Humira lost European patent protection in October 2018.
England’s National Health Service (NHS) says that it has saved £110 million (US $134 million) by implementing its policy to use the best-value adalimumab after the brand-name Humira lost European patent protection in October 2018.
Prior to its loss of patent protection, AbbVie’s Humira was the single medicine on which NHS hospitals spent the most, at £400 million (US $487 million) each year. In preparation for biosimilar availability, the NHS used an approach in which it awarded lots of the adalimumab market to multiple adalimumab manufacturers, and the size of each lot was dependent upon the strength of the offers that drug makers made during the tendering process. The biosimilars now available under the NHS system are Amgen’s Amgevita, Samsung Bioepis’ Imraldi, Sandoz’s Hyrimoz, and Mylan’s Hulio.
The newly announced savings from biosimilar adalimumab come in addition to the £413 million (US $503 million) saved over the past 2 years through the NHS’ concerted efforts to use generics and biosimilars, and the NHS says that it will also “accelerate and widen the uptake of best value biologic medicines” in an effort to save another £400 million to £500 million (US $487 million to $609 million) per year by 2020-2021.
Among the other savings generated during 2018-2019 are £32 million (US $39 million) from biosimilar infliximab, £36 million (US $44 million) from biosimilar etanercept, £45 million (US $55 million) from biosimilar rituximab, and £24 million (US $29 million) from biosimilar trastuzumab.
These savings will be reinvested in new, innovative treatments, says the NHS, noting that “These benefits have only been possible by working closely with patients, clinical teams and NHS trusts.”
Simon Stevens, the NHS’ chief executive, said in a statement that “Use of the best value versions of expensive medicines is already delivering effective treatment for patients across the NHS, including those with cancer, offering the right care for patients while saving the tax payer hundreds of millions of pounds.”
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.